Articles tagged with Phosphatase Inhibitors
A study led by Cold Spring Harbor Laboratory researchers found that inhibiting the protein PTP1B improves learning and memory in an Alzheimer's disease mouse model. This suggests that PTP1B inhibition can also improve microglial function, clearing up Aβ plaques.
Researchers have developed a novel, more selective inhibitor of the human immunoproteasome using a bacterially derived natural product. The new compound targets autoimmune diseases without disrupting other cellular mechanisms.
Researchers have discovered that PR55α, a regulatory subunit of PP2A phosphatase, inhibits p16 expression and blocks cellular senescence induction by γ-irradiation. This finding provides a new insight into the regulation of the p16/RB pathway in response to stressors.
A new antibody created by Cold Spring Harbor Laboratory researchers may offer an effective treatment for some breast cancers. The antibody targets the PTPRD enzyme, which is overabundant in certain breast cancers and helps them spread.
Researchers at University of Würzburg discovered a novel phosphatase inhibitor that selectively blocks the proliferation of tumor cells. This breakthrough targets increased energy demands in diseases like cancer and autoimmune disorders, offering potential new therapies for treatment.
A novel inhibitor has been discovered that stalls a critical enzyme inside tumour cells, locking them in place and preventing invasion into healthy tissue. The findings hold promise for the development of metastasis-blocking agents.
Researchers have discovered a new therapeutic target for Alzheimer's disease, which regulates N-methyl-D-aspartate receptor transport. Valeric acid, an N-methyl-D-aspartate receptor antagonist, has been shown to significantly inhibit the progression of learning and memory disturbances induced by Alzheimer's disease.